Halozyme Signs Exclusive ENHANZE Licensing Agreement With Takeda For ENTYVIO Drug Delivery

Benzinga · 4d ago

Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumab

SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:HALO) today announced the Company entered into a global collaboration and exclusive license agreement with Takeda in December 2025. The agreement provides Takeda with access to Halozyme's ENHANZE® drug delivery technology, the leading proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20), for use with vedolizumab. Vedolizumab is marketed globally as ENTYVIO.